Monitoring the Effects of Glycoprotein IIb/IIIa Antagonists using a Whole Blood Assay of Platelet Microaggregation

Summary

We have used a whole blood single-platelet counting assay (WBSPC) that is sensitive to microaggregation for monitoring GPIIb/IIIa antagonists and have compared this with other methodologies. In vitro effects of the GPIIb/IIIa antagonist fradafiban on ADP-induced platelet aggregation were determined using WBSPC and PRP turbidimetry, comparing citrate and hirudin anticoagulation. Fradafiban was a more potent inhibitor of aggregation assessed by PRP turbidimetry compared to WBSPC. Citrate showed only a trend towards enhancing fradafiban potency (p = 0.087). Citrated blood from 8 patients with unstable angina, randomised to receive oral lefradafiban or placebo, was studied before and during treatment using WBSPC, PRP turbidimetry, impedance aggregometry and Rapid Platelet Function Assay (RPFA, Accumetrics). RPFA, PRP turbidimetry and WBSPC measurements correlated well. Impedance aggregometry responses were oversensitive to GPIIb/IIIa blockade. WBSPC was most discriminating at high levels of inhibition and offered a rapid means of monitoring GPIIb/IIIa antagonist effect within the therapeutic range of inhibition.

Keywords

Platelet aggregation - platelet aggregation inhibitors - unstable angina

• Literatur

• 1 Adgey A. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Eur Heart J 1998; 19: D10-DS21.
• 2 Storey R.F, Wilcox R.G, Heptinstall S. Differential effects of glycoprotein IIb/IIIa antagonists on platelet micro aggregate and macroaggregate formation and effect of anticoagulant on antagonist potency: implications for assay methodology and comparison of different antagonists. Circulation 1998; 98: 1616-21.
• 3 Simoons M.L, Jan de Boer M, van den Brand M.J, van Miltenburg A.J, Hoorntje J.C, Heyndrickx G.R, van der Wieken L.R, de Bono D, Rutsch W, Schaible T.F, Weisman H.F, Klootwijk P, Nijssen K.M, Stibbe J, de Feyter P.J. European Cooperative Study Group. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994; 89: 596-603.
• 4 Tcheng J.E, Harrington R.A, Kottke-Marchant K, Kleiman N.S, Ellis S.G, Kereiakes D.J, Mick M.J, Navetta F.I, Smith J.E, Worley S.J, Miller J.A, Joseph D.M, Sigmon K.N, Kitt M.M, du Mee C.P, Califf R.M, Topol E.J. for the IMPACT Investigators. Multicenter, randomized, double-blind, placebo-controlled trials of the platelet integrin glycoprotein IIb/IIIa blocker Integrum in elective coronary intervention. Circulation 1995; 91: 2151-7.
• 5 Kleiman N.S, Raizner A.E, Jordan R, Wang A.L, Norton D, Mace K.F, Joshi A, Coller B.S, Weisman H.F. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol 1995; 26: 1665-71.
• 6 Smith J.W, Steinhubl S.R, Lincoff A.M, Coleman J.C, Lee T.T, Hillman R.S, Coller B.S. Rapid Platelet-Function Assay: an automated and quantitative cartridge-based method. Circulation 1999; 99: 620-5.
• 7 The Platelet Receptor Inhibition in Ischemic Syndromes Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488-97.
• 8 The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436-43.
• 9 The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention. The Lancet 1997; 349: 1422-8.
• 10 Phillips D.R, Teng W, Arfsten A, Nannizzi-Alaimo L, White M.M, Longhurst C, Shattil S.J, Randolph A, Jakubowski J.A, Jennings L.K, Scarborough R.M. Effect of calcium on GP IIa-IIIa interactions with Integrum: Enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997; 96: 1488-94.